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ANALYSIS IN TAIPEI VETERANS GENERAL HOSPITAL
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Purpose: Most of the current studies were aimed at single histologic type
renal cell carcinoma (RCC). The simultaneous different histologic RCCwere
barely discussed. This study was aimed to these patient with special
clinical features and outcome.
Materials andMethods: We retrospectively reviwed patient in the past 15
years who received operation for renal tumor in Taipei Veterans General
Hospital, and the pathology report revealed RCC with simultaneous tow
different cell type on the same kidney. The demographic data including age
at surgery, sex, body weight index (BMI), comorbidities, and the pre-
operative CT image ﬁndings were collected, as well as the operative
method, pathologic outcome, and further outcome while follow-up.
Results: Total 15 patients were included. The mean age at surgery was
59.3± 13.2 years and mean BMI was 25.3± 4.8 kg/m2. Fourteen patients
were male (86.7%) and 8 (53.3%) had their tumor on the left side. Among
the comorbidities, hypertension accounts for the highest incidence
(46.6%), followed by chronic kidney disease (end-stage renal disease or
polycystic kidney disease, 40%), coronary artery disease (26.7%), type 2
diabetes mellitus (20%) and malignant disease of other organ (20%). There
were only 2 patients (13.3%) having distinct 2 tumors from initial CT image,
and the pathology reported different cell type. Other patient (26.7%) had
incidental the other small tumor in the specimen or there were mixed
histologic feature in single tumor. The average diameter of the main tumor
was 5.1± 2.9 cm and the smaller one 1.4± 1.0 cm. There were 4 patients
(26.7%) having lymph node and distant metastasis at the meanwhile of
diagnosis. According to the AJCC cancer staging (2010), T1a tumor repre-
sented for 20%, T1b tumor 20%, T2a tumor 26.7%, and T3a tumor 6.7%. The
other smaller tumor were all of T1a stage. Most of tumor were classiﬁed as
Fuhrman grade 2 (66.7%), followed by grade 4 (20%) and grade 3 (13.3%).
The operative method were mainly open radical nephrectomy (40%), fol-
lowed by laparoscopic radical nephrectomy (26.7%), open partial ne-
phrectomy (13.3%), robotic-assisted partial nephrectomy (13.3%) and
robotic-assisted radical nephrectomy (6.7%).
The two differnt pathologic cell type of each patient were clear cell with
papillary RCC (20%), clear cell with chromophobe RCC (20%), clear cell with
mucinous tubular and spindle carcinoma (13.3%), and clear cell with clear
cell papillary RCC (13.3%), clear cell and collecting duct carcinoma (6.7%),
papillary and mucinous tubular and spindle carcinoma (6.7%), papillary
and acquired cystic renal disease related carcinoma (6.7%), clear cell and
acquired cystic renal disease related carcinoma (6.7%), and clear cell,
papillary and mucinous tubular and spindle carcinoma (6.7%).
The average follow-up interval was 29.1± 21.1 months. The recurrence
were found in 2 patients, one with clear cell and mucinous tubular and
spindle carcinoma at the 55th month post-OP and the other with papillary
cell and acquired cystic renal disease related carcinoma at the 30th month,
respectively. Three patients with initial distant metastasis expired about 6
months after the surgery, in average.
Conclusion: Simultaneous two histological cell types RCC on the same
kidney was relately rare. Our 15-year data showed various combinations of
two histolytic cell type. However, it is difﬁcult to correlate the prognosis
and clinical outcome with the combination of cell types due to the limited
data of recurrence and 5-year cancer speciﬁc mortality rate.
NDP009:
THE SAFETY AND EFFICACY OF LOW DOSE BCG INTRAVESICAL
INSTILLATION FOR THE TREATMENT OF UREMIC OR KIDNEY
TRANSPLANT PATIENTS WITH RECURRENT UROTHELIAL CARCINOMA
OF THE BLADDER
Wei-Ting Kuo, Chia-Cheng Yu, Tony T. Wu. Division of Urology, Department
of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROCPurpose: Theoretically, immunosuppression is a relative contraindication
for intravesical BCG therapy because of the risk of severe morbidity and
sepsis. We present our experience with intravesical BCG therapy in ure-
mia/renal transplant patients with recurrent urothelial carcinoma of
Bladder.
Materials and Methods: A total of 34 patients with recurrent superﬁcial
bladder cancer (pTa or pT1) were enrolled. Ten patients are uremic and the
other 14 were renal transplantation patient. Intravesical instillation with
low dose (1/2 or 1/3 of 81mg) of BCG was administered weekly for 6
weeks, postoperatively. Boost dose was given at 3 months interval and
then every 6 months until 2 years postoperatively. Cystoscopic examina-
tion was performed every 3 months for the ﬁrst year and semiannually for
2 years and then annually.
Results: Low dose BCG intravesical instillation was completed in 30 pa-
tients. Tumor recurrence was recognized in 2 patients during followup,
who restarted second BCG induction therapy without recurrence. BCG
therapy was withdrawn in 4 patients due to BCG-related local toxicity. No
major complication or systemic dissemination of TB bacili was noted.
Transient dysuria and hematuria are the most common adverse events.
Conclusion: Uremia/renal transplantation patients were traditionally
considered as immuno-compromised and high risk for tumor recurrence.
Low dose BCG intravesical instillation in such patients seems to be a safe
prophylaxis with similar efﬁcacy on tumor control.
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Purpose: Prostate cancer is the 6th most cancer death in Taiwan. There are
no signiﬁcant symptoms and signs in early prostate cancer. MicroRNA is
stable in the cell or tissue and not easily to be degraded. To identify
whether microRNA a potential biomarker for early detection of prostate
cancer, we conducted this study.
Materials and Methods: We collected serum from two different prostate
cancer patients. Serum from other four non-prostate cancer patients was
collected as control group. The QRT-PCR array (782 micro RNAs) was used
to select high speciﬁc expressed microRNAs from serum of prostate cancer
patient. We used above speciﬁc microRNAs to detect serum from 20
prostate cancer patients and 40 non-prostate cancer subjects.
Results: There were 13 microRNAs highly expressed in serum of prostate
cancer patients than control group. After ampliﬁcation, there were only 2
microRNAs highly correlation with prostate cancer. We overexpressed
these 2 microRNAs in LNCaP, increased carcinogenesis in LNCaP was noted.
Conclusion: The microRNA is a potential biomarker in early detection of
prostate cancer.
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THE MOLECULAR MECHANISM OF THE INHIBITORY EFFECT ON
PROSTATE CANCER CELL GROWTH THROUGH THE DIRECT ACTION OF
ESTROGEN ON ESTROGEN RECEPTOR
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Purpose: Hormone replacement therapy is one of treatment choice of
prostate cancer. Estrogen has inhibition of prostate cancer by affect pitu-
itary gland. This negative feedback is lowering level of testosterone not
directly act on prostate cancer cell. To determine whether estrogen has
direct effect on prostate cancer cell, we conducted this study.
Materials and Methods: Choice of two prostate cancer research as the
main material, the ﬁrst detection of estrogen receptors, to see the estrogen
receptor (ER) expression in the case of prostate cells to clarify the
